Skip to main content
Dorothy Sipkins, MD, Oncology, Durham, NC

Dorothy Sipkins MD PhD

Oncology•Durham, NC

Associate Professor of Medicine, Duke University

Join to View Full Profile

  • 2400 Pratt St.Duke UniversityDurham, NC 27705

  • Phone+1 919-668-1002

Dr. Sipkins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Sipkins' Full ProfileAlready have an account?

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2005
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1999

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2014 - 2025
  • IL State Medical License
    IL State Medical License 2005 - 2014
  • MA State Medical License
    MA State Medical License 2002 - 2007
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

Abstracts/Posters

  • PI3K_/_ Inhibitor, Copanlisib, Inhibits Acute Lymphoblastic Leukemia Cell Growth, Increases Survival and Inhibits CNS Disease Progression in Leukemic Mice
    Dorothy A. Sipkins, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting
    GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 MeetingMarch 10th, 2021
  • First Patient with Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
    First Patient with Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359January 30th, 2020
  • GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
    GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359November 13th, 2019
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Dorothy Sipkins, Dr. Dorothy Sipkins, MD, Dr. D Sipkins